USPTO serial 98592556
OPERA
Reviewed by CopyMark Law Group
Status 654
- Filing date
- Status date
- Registration date
- —
- Examiner
- MAHONEY, KATHERINE AILEEN
- Law office
- TMO LAW OFFICE 127
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with OPERA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Cambridge, MA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
TIFFANY D. GEHRKE
TIFFANY D. GEHRKE Marshall, Gerstein & Borun LLP233 S. Wacker Drive, Suite 63006300 Willis TowerChicago, IL 60605Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Oligonucleotide compounds being a component in pharmaceutical preparations for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA compounds being a component in pharmaceutical preparations for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA therapeutic agents for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Nucleic acid therapeutic agents for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Oligonucleotide compounds being a component in pharmaceutical preparations for use in RNA editing for treating genetic diseases; Oligonucleotide compounds being a component in pharmaceutical preparations for use in base editing for treating genetic diseases; Oligonucleotide compounds being a component in pharmaceutical preparations for use as RNA therapeutic for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Oligonucleotide compounds being a component in pharmaceutical preparations for treating genetic diseases that facilitate the editing of RNA base; Pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, nucleic acid therapeutic agents for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; pharmaceuticals, namely, bio-pharmaceutical preparations for the treatment of rare diseases | ACTIVE | — |
| 040 | Custom manufacture of pharmaceuticals, namely, oligonucleotides and RNAs for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 25, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jan 25, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jul 24, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jul 24, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jul 24, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jul 23, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 22, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 22, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 22, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 22, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 22, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 3, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 3, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 3, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 17, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 14, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 10, 2024 | NWAP | NEW APPLICATION ENTERED | — |